The M&A trend isn’t showing any signs of slowing.
Deal volume in health services continues to remain strong, albeit there may be slight variations between activities within certain subsectors, according to a new report.
PwC’s Health Research Institute’s Q2 2019 Deals Insights reports for the US Health Services and Global Pharma & Life Sciences industries reveal that deal volume increased while deal values decreased in both sectors.
As the healthcare industry is facing macroeconomic challenges, both industries are still intensely focused on decreasing pricing (through consumer-centric care and R&D initiatives), which is driving deal activity, according to the report.
“Additionally, when excluding mega-deals from the comparison, Q2 2019 related value grew when compared to the first quarter, further demonstrating the high level of activity with multiples remaining strong,” says Nick Donkar, PwC US Health Services Deals Leader, in relation to the Health Services report.
PwC releases quarterly deals reports that look at the M&A landscape across many sectors.
“The payer and provider landscapes continue to see consolidation both via mega-deals and on a geographical basis,” Donkar says. “We anticipate this trend, both in the provider and the payer subsectors, should continue based on the evolving healthcare landscape in the United States.
“While the ACA’s future, plus macroeconomic factors such as interest rates and tariffs, continue to dominate headlines, industry fundamentals remain favorable to deals,” Donkar adds. “Regulation, policy and tax reform impact, evolving technologies, high costs, cross-industry deals and vertical integration are among the factors driving deal activity.”
It’s important to note, according to Donkar, that the numbers represented in the report are announced deals that have happened in the marketplace.
“However, those numbers do not reflect the amount of activity that's currently happening but has not yet been announced,” he says. “Many parties across all subsectors continue to have conversations that will drive deal activity, so the notion that when deal volume drops something is wrong, is not fully correct. There’s a lot of activity that isn’t in the announcement stage yet, but we know that there’s active conversations happening all the time.”
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Parity for Mental Health — Any Progress?
October 12th 2023Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?
Read More